ITI Pharma and Healthcare Fund Direct Growth
Equity
Direct
Sector - Healthcare
NAV as on 13-03-2025
₹ 15.89
1D
Inception Returns
14.9%
/yr
About ITI Pharma and Healthcare Fund Direct Growth
ITI Pharma and Healthcare Fund Direct Growth is an equity fund. This fund was started on 11 November, 2021. The fund is managed by . The fund could potentially beat inflation in the long-run.
Key Parameters
- ITI Pharma and Healthcare Fund Direct Growth has ₹201 Cr worth of assets under management (AUM) as on Jan 2025 and is less than category average.
- The fund has an expense ratio 0.4.
Returns
ITI Pharma and Healthcare Fund Direct Growth has given a CAGR return of 14.88% since inception. Over the last 1 and 3 years the fund has given a CAGR return of 16.63% and 19.15% respectively.
Holdings
ITI Pharma and Healthcare Fund Direct Growth has allocated its funds majorly in Cash Equivalent, Health, Basic Materials, Industrial. Its top holdings are Sun Pharmaceuticals Industries Ltd, Lupin Ltd, Suven Pharmaceuticals Ltd, Divi's Laboratories Ltd, Apollo Hospitals Enterprise Ltd
Taxation
As it is a sector - healthcare mutual fund the taxation is as follows:For short term (less than a year) capital gains will be taxed at 20%For long term (more than 1 year) capital gains will be taxed at 12.5% without indexation benefitDividends will always be taxed at slab rate. Long term gains upto Rs 1 lakh are exempt capital gains tax.
Investment objective of ITI Pharma and Healthcare Fund Direct Growth
The investment objective of the scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies engaged in Pharma and Healthcare. However, there can be no assurance that the investment objective of the scheme would be achieved.
Minimum Investment and lockin period
Minimum investment for lump sum payment is INR 5000.00 and for SIP is INR 500.00. ITI Pharma and Healthcare Fund Direct Growth has no lock in period.
Historical NAV & Returns
ITI Pharma and Healthcare Fund Direct Growth Overview
| Expense ratio | 0.37% |
Benchmark | S&P BSE Healthcare PR |
| AUM | ₹201 Cr |
| Inception Date | 11 November, 2021 |
| Min Lumpsum/SIP | ₹5000/₹500 |
Exit Load | 1.0% |
| Lock In | No Lock-in |
TurnOver | 61.96% |
| STCG | Selling mutual fund before 1 year, returns taxed at 20%. |
| LTCG | After 1 year, 12.5% tax on returns over ₹1.25 lakh/year. |
| Risk |   Very High Risk |
Trailing Returns
as on (13-Mar-25)
Fund Distribution
as on (31-Jan-25)
- AUM of the fund stands at 200.8 Cr as of Feb'25
- AUM decreased by 15.7 Cr between Feb'25 and Jan'25
Top 3 Sectors in February were Health, Basic Materials & Industrial
Top Growth Drivers | 1M Return |
|---|---|
 Glaxosmithkline Pharmaceuticals Ltd | 13.6% |
 Abbott India Ltd | 3.6% |
 Suven Pharmaceuticals Ltd | 2.6% |
ITI Pharma and Healthcare Fund Direct Growth Highlights
Very High Risk
About the fund
Fund Allocations
AUM size ₹201 Cr
Expense Ratio 0.37%
Frequently Asked Questions for ITI Pharma and Healthcare Fund Direct Growth
ITI Pharma and Healthcare Fund Direct Growth | Absolute Returns | CAGR Returns |
1 Month Returns | -4.2% | -4.2% |
6 Month Returns | -12.61% | -12.61% |
1 Year Returns | 16.63% | 16.63% |
3 Years Returns | 69.17% | 19.15% |
5 Years Returns | 0% | 0% |
- Click Buy on the fund name.
- Input the amount you are looking to invest.
- Select Lump Sum or SIP (Weekly, Monthly or Quarterly).
- Select your bank account and proceed with Payment.
Fund Name | Alpha 1 Year | Alpha 3 Years | Alpha 5 Years |
ITI Pharma and Healthcare Fund Direct Growth | 3.47 | 2.85 | - |
Fund Name | Beta 1 Year | Beta 3 Years | Beta 5 Years |
ITI Pharma and Healthcare Fund Direct Growth | 0.97 | 0.9 | - |
Fund Name | Sharpe Ratio 1 Year | Sharpe Ratio 3 Years | Sharpe Ratio 5 Years |
ITI Pharma and Healthcare Fund Direct Growth | 0.25 | 0.79 | - |
Fund Name | Standard Deviation 1 Year | Standard Deviation 3 Years | Standard Deviation 5 Years |
ITI Pharma and Healthcare Fund Direct Growth | 19.51 | 16.13 | - |